Dogwood Therapeutics DWTX Amortization expense related to capitalized debt issuance costs

Amortization expense related to capitalized debt issuance costs at other companies

Comfort Systems USAFIX

$232K+37.3%

MicroStrategyMSTR

$6.52M+7.7%

Cloudflare, Inc.NET

$2.43M+145%

Realty IncomeO

$8.82M+49.0%

NXP SemiconductorsNXPI

$2M+100%

Ubiquiti Inc.UI

$321K-1.2%

Operating income-$5.1M-14.6%

Net income-$5.0M+54.4%

EPS (diluted)-$0.15+98.2%

Cash & equivalents$13.2M-24.6%

Total debt$144.9K-24.2%

Total equity$80.6M+1,038%

Total assets$95.2M-1.8%

Operating cash flow-$4.6M+2.0%

Market cap$54.14M-57.6%

Enterprise value$41.06M-64.7%

Return on equity-64.6%-29.8pp

Debt / equity0×0.0×

Current ratio5.9×-1.6×

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Dogwood Therapeutics's amortization expense related to capitalized debt issuance costs?: Dogwood Therapeutics (DWTX) reported amortization expense related to capitalized debt issuance costs of $52.37K in Q1 2025.
How has Dogwood Therapeutics's amortization expense related to capitalized debt issuance costs changed year-over-year?: Dogwood Therapeutics's amortization expense related to capitalized debt issuance costs increased by 258.5% year-over-year, from $14.61K to $52.37K.